Dose-dense chemotherapy for aggressive non-Hodgkin lymphoma.
Non-Hodgkin lymphoma is a heterogeneous disease that represents the seventh leading cause of cancer death. Second-generation and third-generation chemotherapy regimens have only produced a marginal improvement in outcome over the administration of the cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in aggressive forms of non-Hodgkin lymphoma. This has led to the development of different strategies for improving disease-free and overall survival in this disease. Dose intensification achieved by condensing the intervals between each chemotherapy cycle is possible with granulocyte colony-stimulating factor support, which reduces neutropenia and its complications. Clinical trials indicate that this strategy may improve the outcomes in patients with aggressive non-Hodgkin lymphoma, particularly elderly patients. Nurses can play a major role in the implementation of evidence-based supportive care strategies in clinical practice to ensure safe use of dose-dense chemotherapy regimens.